Modification methods | Anchoring motif | Targeting molecule | Cargo | Effect | References |
---|---|---|---|---|---|
Lipid insertion | DSPE-PEG | RGD | Tetraacetylated N-azidoacetyl-d-mannosamine (Ac4ManNAz) | Increased targeting to blood vessels and synergistic therapeutic angiogenesis effect and angiogenesis imaging | [136] |
AA | PTX | Profound ability to accumulate in cancer cells upon systemic administration and improved therapeutic effects | [78] | ||
Angiopep-2 | Docetaxel | Targeted GBM delivery and therapy | [137] | ||
Angiopep-2 | Signal transducers and activators of transcription 3 (STAT3) siRNA | Xenograft growth inhibition due to BBB penetration, and enhanced median survival rate of the tumor-bearing nude mice | [138] | ||
DOPE-PEG | RVG peptide | N.A | Improved targeting towards the cortex and hippocampus, greatly reduced plaque deposition and Aβ levels, decreased activity of astrocytes, and improved cognitive function of APP/PS1 mice, as determined by the Morris water maze test | [139] | |
Cholesterol | AS1411 aptamer | let-7 miRNA | Targeted breast cancer delivery and tumor growth inhibition | [140] | |
PSMA aptamer, EGFR aptamer and folate | Survivin siRNA | Tumor growth inhibition in prostate cancer xenograft, orthotopic breast cancer models, and patient derived colorectal cancer xenograft | [141] | ||
Diacyllipid-PEG | Aptamer sgc8 | Doxorubicin | Selective cancer cell targeting and high therapeutic efficacy in vitro | [142] | |
C18-PEG, DSPE-PEG, Cholesterol-PEG | AS1411 aptamer | PTX | Increased chemotherapeutic effects and decreased side effects in vivo | [143] | |
Chemical ligation | Amino group based EDC/NHS coupling chemistry and azide-alkyne cycloaddition chemistry | c(RGDyK) peptide | Curcumin (MSC-derived EVs) | Ischemic brain tissue targeting in the transient middle cerebral artery occlusion mice model, and strong suppression of the inflammatory response and cellular apoptosis in the lesion | [82] |
c(RGDyK) peptide | miR-210 | Ischemic brain tissue targeting in the transient middle cerebral artery occlusion mice model and enhanced animal survival rate | [145] | ||
Neuropilin-1-targeted peptide (RGE) | Superparamagnetic iron oxide nanoparticles and curcumin | BBB penetration, good results for targeted imaging and therapy of glioma in the orthotopic glioma model | [144] | ||
Thiol group based thiol-maleimide conjugation | Alexa488 (for imaging) | N.A | Quantitative analysis of the cellular delivery and intracellular traffic of EVs | [146] | |
Metabolic labeling | Azide group originating from L-azidohomoalanine supplement or tetra-acetylated N-azidoacetyl-D-mannosamine in culture medium | Biotin/FITC | N.A | Imaging analysis of EVs in cells and excellent potential for targeted delivery | [147] |
Azide group originating from tetra-acetylated N-azidoacetyl-D-mannosamine in culture medium | Azadibenzylcyclooctyne-fluorescent dyes | N.A | Analysis of the uptake and distribution of EVs in vitro and in vivo | [148] | |
Affinity binding | CP05 | M12 peptide | Phosphorodiamidate morpholino oligomer | enhanced dystrophin-positive myofibers in muscles and functional rescue | [149] |
Thioketal-mPEG (assisted by Chlorin e6 and ultrasound irradiation) | Bmp7 mRNA | Phagocytosis escape from non-target organs, targeted delivery of Bmp7 mRNA into omental adipose tissue (OAT) and induced OAT browning | [151] | ||
N.A | KV11 peptide | Greatly enhanced anti-angiogenic effects over KV11 peptide | [152] | ||
Transferrin | Superparamagnetic nanoparticles | Doxorubicin | Excellent in vivo targeting ability and cancer inhibition effect | [153] | |
C1C2 domain of lactadherin | EGFR nanobody | N. A | Specific uptake by EGFR-overexpressing tumor cells | [157] | |
(RGD)-4C peptide | Neural progenitor cell derived-EVs | Lesion region targeting and suppressed inflammatory response in the MCAO mouse model | [158] | ||
GPI anchor signal peptide derived from DAF | Anti-EGFR nanobodies | N.A | Improved EV binding to EGFR-expressing tumor cells | [135] | |
HepG2 cells derived EVs | Aptamer LZH8 | FITC conjugated by DNA hybridization chain reaction | Fluorescence modification of specific EVs | [154] | |
Enzymatic conjugation | Vesicle membrane protein containing N-terminal glycine and leucine residues | EGFR-targeting peptides or anti-EGFR nanobodies | PTX | Increased accumulation in EGFR-positive cancer cells and significantly increased drug efficiency in a xenografted mouse model of EGFR-positive lung cancer | [156] |